Stockreport

Wave Life Sciences' (WVE) RNA Obesity Drug WVE-007 Shows Potential to Match GLP-1 Efficacy Without Muscle Loss [Yahoo! Finance]

Wave Life Sciences Ltd. - Ordinary Shares  (WVE) 
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am Check Earnings Report
PDF positive interim results from its Phase 1 INLIGHT trial evaluating WVE-007, which is an investigational RNA medicine for obesity. The data from the 240 mg single-dose co [Read more]